ReviewMyManuscript logo
Review My ManuscriptAI-assisted pre-review
Illustrative AI review — based on a real open-access article (Lise Beier Havdal et al., Frontiers in Pediatrics, 2022; DOI: 10.3389/fped.2022.1004739; License: CC-BY 4.0). Not a real journal decision.
Sample / illustrative report only — fictional neuro-oncology manuscript for UI demo. Not a real patient case, not a journal decision. Upload your own manuscript to receive a real review.
ANALYSIS REPORTFictional sample05.07.2026

Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age

Font size:
View:

This is a concise overview. Switch to Full evaluation (Detailed) above for the complete report.

Key Points

  • 1Norwegian NorEPIS prospective surveillance cohort of 1,096 laboratory-confirmed RSV cases under 59 months (2015–2018) identifying risk factors for severe disease; pre-specified severity definition and multiple imputation strengthen validity, but missing palivizumab data and modest ethnic diversity limit generalisability.

Major Issues

Methods: Palivizumab prophylaxis status is not captured; palivizumab is given to high-risk groups (premature infants, congenital heart disease, chronic lung disease) who overlap substantially with the risk groups identified in this study; its omission may confound the estimated effect of gestational age and chronic pulmonary disease on severity.
Methods / Results: The composite severity outcome pools hospitalisation ≥3 days, ICU admission, and oxygen requirement — events of widely differing clinical severity; a child requiring overnight supplemental oxygen is categorised identically to one requiring mechanical ventilation, which may attenuate detection of risk factors specific to the most severe presentations.
Methods: Household smoking is defined by parental self-report at enrolment without validation against carbon monoxide measurement or cotinine levels; exposure misclassification from social desirability bias may attenuate the smoking-severity association.

Priority Action Plan

HIGH IMPACT

Problem

Disaggregate composite severity outcome and report separate logistic regression models for ICU admission and oxygen requirement as secondary endpoints.

Why it matters

Composite outcomes pool events of different severity; ICU-specific risk factor data are directly relevant to RSV vaccine prioritisation guidelines.

Suggested fix

Disaggregate composite severity outcome and report separate logistic regression models for ICU admission and oxygen requirement as secondary endpoints.

HIGH IMPACT

Problem

Add a quantitative bias analysis for palivizumab confounding in the preterm and chronic lung disease subgroups, or obtain palivizumab data from surveillance records.

Why it matters

Palivizumab is given precisely to the highest-risk RSV groups; without adjustment, the preterm and CLD risk estimates may be underestimated.

Suggested fix

Add a quantitative bias analysis for palivizumab confounding in the preterm and chronic lung disease subgroups, or obtain palivizumab data from surveillance records.

MEDIUM IMPACT

Problem

Add LMIC generalisation discussion and complete-case sensitivity analysis alongside multiple imputation results.

Why it matters

RSV burden is highest in LMICs; a globalisation statement is important given that the new RSV vaccine pipeline is most relevant for those settings.

Suggested fix

Add LMIC generalisation discussion and complete-case sensitivity analysis alongside multiple imputation results.

Quick win: This is a high-quality surveillance study with strong prospective design and pre-specified outcomes. The revisions are targeted and achievable: disaggregate the composite outcome, address palivizumab confounding, and add global context. These changes would strengthen an already well-executed study.

Upload your manuscript
Open interactive sampleHow journal fit worksSample reports hubDesk-reject guides
Illustrative AI review sample — pediatrics | Review My Manuscript